Your email has been successfully added to our mailing list.

×
0 0 0.000463499420625797 0.000463499420625797 0.00011587485515649 0 0 0
Stock impact report

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity [Yahoo! Finance]

Nasdaq, Inc. (NDAQ) 
Last nasdaq, inc. earnings: 4/22 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.nasdaq.com
Company Research Source: Yahoo! Finance
Dr. Shoemaker quote · GlobeNewswire Inc. IMCIVREE packaging IMCIVREE packaging with vial · GlobeNewswire Inc. IMCIVREE 3D Render IMCIVREE 3D Render · GlobeNewswire Inc. -- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] -- -- Company to host conference call today at 7:00 p.m. ET -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno Show less Read more
Impact Snapshot
Event Time:
NDAQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NDAQ alerts
Opt-in for
NDAQ alerts

from News Quantified
Opt-in for
NDAQ alerts

from News Quantified